Browse Articles

Discover research articles across all indexed journals

Preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus Calmette-Guérin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with HER2 expression: A prospective, open label, single-center study.

Journal of Clinical Oncology Yijun Shen, Liangju Peng, Weijie Gu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.775

775 Background: Current treatment for high-risk non-muscle invasive bladder cancer (HR-NMIBC) involves Bacillus Calmette-Guérin (BCG) therapy, or radical cystectomy (RC) especially for patients with very-high-risk features. However, 40%-60% HR-NMIBC pts will relapse after BCG treatment. Moreover there are a high incidence of postoperative complications and a negative impact on health-related quality of life after RC. Disitamab Vedotin (DV) is a novel antibody drug conjugate (ADC) that targets the HER2 protein, however its efficacy and safety in HR-NMIBC are limited.We conducted a prospective, open label, single-center study to evaluate the value of RC48 combined with BCG in HR-NMIBC pts. Methods: In this study, two cohorts of BCG-naive pts with very-high-risk features who refused to undergo RC or did not meet the requirements of RC with HER2 expression (IHC 1+/2+/3+) were enrolled (Cohort A:pts were unable to undergo complete tumor resection or have CIS. Cohort B: pts underwent complete tumor resection). All pts will receive eight cycles of intravenous injection of DV (2mg/kg, once every three weeks) and at least one year of BCG intravesical instillation. The Primary endpoints included the 3-month cCR rate in Cohort A and the 6-month EFS rate in Cohort B. The secondary endpoints were to evaluate additional efficacy end points and safety. Results: From Dec 2023 to Aug 2024, twenty eligible pts(16 male;4 female)were enrolled, with 15 pts in Cohort A and 5 pts in Cohort B. 17 of pts had HER2 high expression (2+ or 3+), and 3 of them had HER2 low expression (1+). As a cut-off date (12-Sep-2024), the cCR rate at 3 months and 6 months were both 100% in 11 and 5 pts of Cohort A and the EFS rate at 6 months was also 100% in 3 pts of Cohort B. 65% (13/20) pts experienced treatment-related adverse events (TRAEs). The most common TRAEs included AST/ALT increase 40%(8/20) ,alopecia 45% (9/20), peripheral sensory neuropathy 35% (7/20), anorexia 10% (2/20) and rash 5% (1/20). Grade 3 TRAEs occurred in 10% (2/20) pts with one peripheral sensory neuropathy caused by DV and one hematuria caused by BCG. 60% (12/20) pts had BCG-related AEs including bladder irritation, fever, arthralgia, conjunctivitis and hematuria. Conclusions: This was the first study to evaluate DV in combination with BCG in the treatment for HR-NMIBC. Preliminary results showed the combination had promising efficacy with a manageable safety profile. This may potentially provide a new bladder-sparing therapy for very HR-NMIBC pts with HER2 expression who refused RC or did not meet the requirements of RC. Clinical trial information: NCT06187506 .

Evaluating clinical tools to monitor cardiovascular (CV) risk in men with localized high-risk or locally advanced prostate cancer (LHRPC) treated with hormone therapy (HT).

Journal of Clinical Oncology Neha Venkatesh, Pankaj Kumar Chauhan, Kabir Grewal et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.116

116 Background: Androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSIs) indirectly increase CV risk. There are no risk estimation tools specific to men with prostate cancer undergoing HT. Current practice utilizes tools designed for the general population, such as the AHA/ACC ASCVD risk score. Herein, we investigate the applicability of such general population risk tools in men receiving pre-operative HT for LHRPC. Methods: We conducted a retrospective analysis of men with LHRPCa who received 6 months of pre-operative ADT + apalutamide +/- abiraterone on NCT. Cardiometabolic factors of interest were extracted from the electronic medical record, and ASCVD risk scores were calculated alongside metabolic syndrome (MetS) Z scores (calculated using ASCVD calculator https://tools.acc.org/ldl/ascvd_risk_estimator/#!/calulate/estimator/ and metabolic syndrome severity calculator https://metscalc.org/metscalc/ ). Results: Sixty-four patients had data available to calculate baseline and end-of-treatment (EOT) ASCVD risk and MetS Z scores. Prior to initiation of HT, 46.8% of patients were on antihypertensive treatment, 11.3% had diabetes mellitus, and 45.2% were on lipid-lowering therapy. After 6 months of ADT + ARSI, the median change in ASCVD risk score was 0.95, and 21% of patients exhibited a clinically significant increase in ASCVD risk score of ≥ 2.5%. The median change in the metabolic syndrome Z score was -0.36, indicating a decrease in metabolic syndrome risk. 28% of all patients demonstrated an increase in metabolic syndrome risk after 6 months of HT. Conclusions: Despite the known association between HT and increased CV risk, most patients in this study did not experience a clinically meaningful increase in either ASCVD risk or MetS Z score. These findings suggest that general population risk estimation tools may not reflect temporal evolution of CV risk in patients undergoing HT. This study also highlights an unmet need for novel risk assessment tools specifically tailored to identify at-risk men among those treated with HT.

A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting.

Journal of Clinical Oncology David Yoonsuk Oh, Deepak Kilari, Christopher Darr et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps434

TPS434 Background: There are currently no standard neoadjuvant treatments for patients with localized prostate cancer despite improved outcomes with neoadjuvant therapy in multiple other solid tumors. Xaluritamig is a bispecific T-cell engager (TCE) that simultaneously engages the six-transmembrane epithelial antigen of the prostate 1 (STEAP1) expressed on prostate cancer cells and the CD3 complex on T cells, thereby leading to T-cell mediated lysis of the STEAP1 expressing prostate cancer cells. In an ongoing trial (NCT04221542), xaluritamig has demonstrated deep, early, and durable responses in patients with metastatic castration-resistant prostate cancer. Notably, TCEs as a class of therapy have demonstrated the potential to have even greater efficacy and safety when used in earlier stages of disease where the overall disease burden is less and immune fitness is generally better. These data suggest that xaluritamig may be safely administered in the neoadjuvant setting and lead to pathologic responses with subsequent improvement in disease control and long-term clinical outcomes. In the current study, safety and feasibility as well as preliminary efficacy of neoadjuvant xaluritamig are being evaluated in patients with newly diagnosed localized intermediate or high-risk prostate cancer. Methods: This Phase 1b, open-label, multicenter study plans to enroll approximately 30 patients diagnosed with localized intermediate or high-risk prostate cancer and are planned for radical prostatectomy. Eligibility criteria includes histologically or cytologically confirmed prostate adenocarcinoma with Gleason Score ≥4+3 and an initial prostate specific antigen (PSA) of ≥10 ng/ml, no evidence of metastasis outside of the surgical resection field (PSMA-PET positive locoregional lymph nodes or less or equal 5 local lymph nodes on MRI can be enrolled), or use of any prior therapy for prostate cancer. The study includes a 28-day screening period, a two-cycle neoadjuvant treatment period (each cycle lasting 28 days), a safety follow-up visit (up to 42 days) after surgery, and a long-term follow-up period (up to 42 months). The last dose of xaluritamig will be administered about 14 to 28 days prior to undergoing radical prostatectomy. Primary outcomes will evaluate xaluritamig through treatment-emergent and treatment-related adverse events, and feasibility of radical prostatectomy. Secondary outcomes will assess PSA response, imaging-based response on multiparametric magnetic resonance imaging (mpMRI) prior to prostatectomy, pathologic response and the pharmacokinetics of xaluritamig. The study is open for enrollment as of October 2024. Clinical trial information: NCT06613100 .

Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC).

Journal of Clinical Oncology Guru P. Sonpavde, Begoña P. Valderrama, Karim Chamie et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps893

TPS893 Background: It is hypothesized that V940 (mRNA-4157), an individualized neoantigen therapy consisting of an mRNA encoding up to 34 tumor neoantigens, will work in synergy with immune checkpoint inhibitors by generating de novo tumor-specific T-cell activity. In a phase 2 trial of patients with high-risk melanoma, adjuvant V940 + pembrolizumab had a manageable safety profile and improved recurrence-free and distant metastasis–free survival versus pembrolizumab monotherapy. The phase 1/2 INTerpath-005 study (NCT06305767) has 2 cohorts. The phase 1 open-label, single-arm perioperative cohort will evaluate perioperative (neoadjuvant and adjuvant) V940 + pembrolizumab + EV for muscle-invasive bladder cancer (MIBC). The phase 2 double-blind, randomized adjuvant cohort will evaluate adjuvant V940 + pembrolizumab versus placebo + pembrolizumab for high-risk MIUC. Methods: Eligibility criteria for the perioperative cohort include age ≥18 years, diagnosis of MIBC (T2-T4aN0M0 or T1-T4aN1M0) with urothelial carcinoma histology, eligibility and willingness to undergo radical cystectomy (RC) + pelvic lymph node dissection (PLND), and cisplatin ineligibility. Eligibility criteria for the adjuvant cohort include age ≥18 years, diagnosis of MIUC with predominant UC histology, radical resection ≤7 weeks before providing informed consent and ≤14 weeks before randomization, high-risk pathologic disease (ypT2-4a and/or ypN+ after neoadjuvant chemotherapy [NAC]; pT3-4a and/or pN+ without NAC), and cisplatin ineligibility. In the perioperative cohort, approximately 30 patients will receive neoadjuvant pembrolizumab 200 mg IV on day 1 Q3W × 4 cycles + EV 1.25 mg/kg IV on days 1 and 8 Q3W × 4 cycles + V940 1 mg IM on day 1 Q3W × 1-4 doses. Patients will undergo RC + PLND followed by adjuvant pembrolizumab 200 mg IV on day 1 Q3W × 13 cycles + EV 1.25 mg/kg IV on days 1 and 8 Q3W × 5 cycles + V940 1 mg IM on day 1 Q3W × 5-8 doses, depending on number of doses administered in neoadjuvant period, for a total of 9 doses. In the adjuvant cohort, approximately 200 patients will be randomly assigned 1:1 to receive pembrolizumab 400 mg IV Q6W × 9 cycles + V940 1 mg IM Q3W × 9 doses or pembrolizumab 400 mg IV Q6W x 9 cycles + placebo IM Q3W x 9 doses. Randomization in the adjuvant cohort will be stratified by circulating tumor DNA status at screening (positive vs negative vs not evaluable) and prior NAC (yes vs no). The primary end points are safety (perioperative cohort) and DFS per investigator assessment (adjuvant cohort). Secondary end points are pathologic complete response and pathologic downstaging (perioperative cohort); overall survival, distant metastasis–free survival per investigator, safety, and tolerability (adjuvant cohort). Clinical trial information: NCT06305767 .

Analysis of gut microbiota profiles in patients with prostate cancer: The PROMISE-JAPAN study.

Journal of Clinical Oncology Koji Hatano, Toshiki Oka, Takuji Yamada et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.212

212 Background: Prostate cancer (PCa) is clinically associated with dietary habits such as high-fat diets. The gut microbiota is strongly influenced by dietary habits and is involved in the host immune response and metabolic pathways. Recently, the gut microbiota has been shown to influence a variety of diseases, including PCa. We have found that the gut microbiome and its metabolite, short-chain fatty acids (SCFA), promote cancer growth in PCa mouse models. To clarify the association between gut microbiota and PCa in humans, we conducted a study of PCa, gut microbiome, and lifestyle in Japan (PROMISE-JAPAN). In this study, we evaluated the gut microbiota profiles in PCa patients with a particular focus on differences between non-metastatic PCa (nmPCa) and metastatic PCa (mPCa). Methods: This multicenter, prospective, observational study enrolled 869 Japanese patients between 2020 and 2022. Eligibility criteria were men with suspected PCa who underwent prostate biopsy, and rectal swab samples were collected before prostate biopsy. Men who had taken antibiotics within 6 months before sample collection or whose previous antibiotic use was unknown were excluded. The gut microbiota composition was analyzed using 16S rRNA gene sequencing. The raw sequencing data was processed by the QIIME2 pipeline. The Mann-Whitney U tests were used to compare characteristics between groups. Results: A total of 723 participants were eligible for analysis, including 262 men without cancer and 461 men with PCa, including 56 men with mPCa. The composition of the gut microbiota differed significantly between the non-cancer and the PCa group, with PCa having more Lachnospiraceae, which produce SCFA. The mPCa group had a higher abundance of Ruminococcaceae (UCG-005 and NK4A214), which belong to the Firmicutes pylum, compared to the nmPCa group. The mPCa group had a lower abundance of Prevotella, which belongs to the Bacteroidota pylum, compared to the nmPCa group. In mPCa compared to nmPCa, 19 gut microbiota pathways were significantly altered. In particular, the androstenedione degradation pathway was significantly increased in the mPCa group (p=0.0287). Conclusions: The composition of the gut microbiota differed between the non-cancer, the nmPCa and the PCa group. The gut microbiome associated with androgen metabolism was more common in mPCa patients. Clinical trial information: UMIN000043489 .

RadOnc-GPT (gpt-4o) versus human data extraction for prostate cancer clinical research.

Journal of Clinical Oncology Mohammad Javad Namazi, Mariana Borras Osorio, Jason M Holmes et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.425

425 Background: Prostate cancer (PC) ranks among the most prevalent cancers in men, with incidence rising due to factors like aging populations and enhanced screening techniques. Effective data extraction from clinical records is crucial for advancing research and improving patient care; however, traditional manual methods can be time-consuming and susceptible to mistakes. This study seeks to evaluate RadOnc-GPT against human annotation for extracting essential clinical information from prostate cancer clinical records. Methods: RadOnc-GPT is a retrieval augmented generation (RAG)-based chatbot with access to a variety of patient data including treatment details, radiology reports, and clinical notes. RadOnc-GPT uses Open AI’s gpt-4o model. Patients who received curative intent radiotherapy as initial treatment for PC in our institution between 2014 and 2023 were randomly selected for evaluation. Relevant Clinical factors were extracted by a human expert annotator on our on-site RedCap database. The extraction of the same variables was performed using RadOnc-GPT. A comparison between the ground truth (human annotation) and RadOnc-GPT, to evaluate the performance of the AI system, was carried out including accuracy, recall and F1 score. Results: A total of 382 PC patients were included in the cohort for data extraction. The clinical variables extracted were the treatment intent, NCCN risk category, T and N stage, Gleason score, radiation volume, and Androgen Deprivation therapy (ADT) use. The overall performance of RadOnc-GPT was excellent, with the highest accuracy achieved for treatment intent (99.7%), Gleason score (98.4%), and Treatment Volume (90.1-99.5%). Conclusions: RadOnc-GPT performed excellent at extracting relevant clinical details from the electronic medical record and radiation oncology information systems with dramatic reduction in time and cost compared with manual review. LLMs could be highly useful for large-scale data extraction in PC research, offering a promising solution for automating the accurate data extraction process. Correct (n) Total (n) Accuracy Recall F1 score RT with curative intent 381 382 99.7 99.9 99.9 Prostate Cancer Risk Category 345 382 90.3 90.4 95.1 Primary tumor staging (T) at diagnosis 368 382 96.3 96.3 97.9 Regional nodal status (N) at diagnosis 352 382 92.1 92.2 95.9 Gleason Score Primary Secondary Total 376372376 382382382 98.497.498.4 98.597.498.5 99.298.799.2 Treated Areas Prostate Pelvic Nodes Para-Aortic Nodes Distant Site 380344378372 382382382382 99.590.19997.4 99.490.199.197.4 99.79599.598.7 ADT Use with RT 365 382 95.5 95.7 97.8

Clinically advanced prostate cancer (CAPC) in extremely young men: A genomic landscape study.

Journal of Clinical Oncology Rebecca A Sager, Andrea Necchi, Roger Li et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.210

210 Background: CAPC arising in young patients is a challenging disease with significant need for improvements in systemic therapies, especially for patients with surgically incurable disease. Here we sought to explore the genomic landscape to generate hypotheses and inform clinic trial design. Methods: 13 cases of CAPC in men under the age of 39 years (CAPC <39) and 23,364 cases of CAPC in men 50 or older (CAPC >50) underwent comprehensive genomic profiling (CGP) to examine all classes of genomic alterations (GA). MSI high status, tumor mutation burden (TMB) levels, genomic ancestry and trinucleotide mutational signatures were determined from the sequencing data. HRDsig status was calculated using a broad set of genome-wide copy number features. PD-L1 was determined by IHC using the Dako 22C3 tumor proportional score system. Results were compared using the Fisher exact system with the Benjamini-Hochberg adjustment to correct for false discovery. Results: The GA rates were similar in the very young and more senior patient cohorts (3 GA/tumor for both groups). Genomic ancestry distribution revealed more African ancestry cases in the CAPC <39 group (30.8% vs 15.1%; NS) and more European ancestry in the CAPC >50 group (75.1% vs 53.9%; NS). MSI high status was trending more common in the CAPC <39 group (7.7% vs 3.0%; NS) as was a positive HRD signature (15.4% vs 10.2%; NS). The median TMB levels were low and similar in both groups (range 1.3 to 2.4 mut/Mb) as was the frequency of TMB > 10 mut/Mb (range 4.3% to 7.7%). Defined trinucleotide signatures were rare and similar in both groups. PD-L1 expression was available for a subset of the of the cases and showed no distinct differences. GA in genes associated with HRD were trending more frequent in the younger cohort including BRCA1 (7.7% vs 1.1%; NS), BRCA2 (15.4% vs 8.0%; NS), ATM (7.7% vs 5.7%; NS) and PALB2 (7.7% vs 0.7%; NS). Other GA more frequent in the CAPC <39 group included BRAF (15.4% vs 4.0%; NS), CDK12 (7.7% vs 4.9%; NS), CDKN2A (15.4% vs 2.5%; NS), CDKN2B (7.7% vs 1.5%; NS), MTAP (7.7% vs 1.4%; NS), PTEN (46.2% vs 31.2%; NS), RB1 (7.7% vs 4.8%; NS), TP53 (53.8% vs 37.9%; NS) and TMPRSS2 - ERG fusions (38.5% vs 31.7%; NS). GA in AR (11.3% vs 7.7%; NS), SPOP (10.9% vs 0%; NS) and PIK3CA (6.4% vs 0%; NS) were more frequent in the CAPC >50 group. Conclusions: In contrast with CAPC arising in men >50, CAPC arising in extremely young men under 39 featured relatively different frequencies of biomarker and GA distribution, without reaching statistical significance. Our results are hypothesis-generating; limitations include the small sample size of patients < 39, retrospective nature, potential selection bias, and lack of clinical outcomes annotation. <39 years >50 years P value AFR Ancestry 30.8% 15.1% NS EUR Ancestry 53.9% 75.1% NS BRAF 15.4% 4.0% NS BRCA2 15.4% 8.0% NS CDK12 7.7% 4.9% NS PTEN 46.2% 31.2% NS SPOP 0.0% 10.9% NS MSI High 7.7% 3.0% NS TMB > 10 mut/Mb 7.7% 4.3% NS

The Oncopig bladder cancer model, an innovative large animal platform for evaluating treatment effects.

Journal of Clinical Oncology Viranda Jayalath, Andreas Autlitzky, Natalia Kudinova et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.857

857 Background: Bladder cancer carries a high recurrence rate despite availability of several treatment options including surgery, chemotherapy, radiation, and immunotherapy, resulting in the highest cost of lifelong treatment per patient and highlighting the need for development of novel diagnostic and therapeutic strategies. Unfortunately, results from current bladder cancer models do not effectively translate to clinical practice (mouse models) or are rare and not inducible (canine models). This, in addition to the use of endoscope-based approaches for bladder cancer treatment highlights the critical need for large animal bladder cancer models to improve patient outcomes. Pigs represent an ideal platform that provide both regulatory acceptable and clinically relevant large animal cancer models due to their similar physiology, size, genetics, immunity, and metabolism in relation to humans. The Oncopig bladder cancer model is an ideal tool for testing endoscopic and other oncolytic-based treatments. Methods: The Oncopig cancer model develops tumors following induced expression of KRAS G12D and TP53 R167H driver mutations utilizing an adenoviral vector encoding Cre recombinase (AdCre). Two procedures for cystoscope-based AdCre delivery were evaluated. In procedure I (Proc-I) a combination of AdCre and N-Dodedcyl-beta-maltoside, a sugar-like surfactant utilized to dissolve the glycoaminoglycans layer, was instilled into the bladder (1h; n=3). In procedure-II (Proc-II) the bladder urothelium was superficial denuded at 3 sites and subsequent AdCre was instilled into the bladder (1h; n=4). Oncopigs underwent CT scans and follow-up cystoscopy, and were euthanized at 3 timepoints (day 14, 21, and 28) to assess temporal bladder tumor growth. Tumor samples were collected at necropsy for histopathological evaluation (H&E, TP53, Ck34be12, vimentin, and CD3) and to evaluate tumor stage. Results: In total 6/7 Oncopigs developed endoluminal tumors. Tumor-induction efficacy was 100% for Proc-I (n=3/3) and 75% for Proc-II (n=3/4). Two tumor types were observed: urothelial cell carcinomas of sarcomatoid variant (Proc-I: n=3/3; Proc-II: n=2/4) and inflammatory tumors (Proc-II: n=1/4). After 14 days, pT1 tumors were observed for Proc-I, while pT2 tumors were observed for Proc-II. After 21 days, both pT1 and pT2 tumors were observed for Proc-I, while Proc-II tumors remained pT2. Conclusions: The Oncopig bladder cancer model can develop both superficial and muscle invasive urothelial cell carcinomas with sarcomatoid variant. Tumors develop rapidly (within 2 weeks), with tumor invasiveness correlated with time post tumor induction and procedure used, making this an ideal model for evaluation of novel therapeutic approaches. Further exploration and development of additional tumor models including further translational characterization will be important for broader utility.

Association of a novel AI-based digital pathology (CHAI) biomarker with progression free survival (PFS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology Georges Gebrael, Vrishab Krishna, Nicolas Sayegh et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.204

204 Background: In mHSPC, no baseline biomarker reliably predicts progression-free survival (PFS). Identifying pts unlikely to benefit from current therapies could enable personalized management and better pt selection for clinical trials. Herein, we investigate the capacity of a novel AI-based digital pathology platform to prognosticate in mHSPC. Methods: Pts diagnosed with mHSPC with available pathology slides and undergoing systemic therapy at the Huntsman Cancer Institute, University of Utah were eligible. Whole slide images were generated from digital scans of diagnostic H&E histopathology specimens reviewed by board-certified genitourinary pathologists. The CHAI (Correlative Histologic AI) platform was used to segment nuclei and extract morphologic and spatial features. Association with PFS was assessed across extracted features, and a biomarker signature was generated. Kaplan Meier estimators, log-rank tests and t-tests were used to compare outcomes among those with and without the biomarker signature for time-to-event and binarized endpoints respectively. PFS was defined from the start of therapy for mHSPC to biochemical or radiographic progression (per PCWG2) or death. Multivariate analysis for PFS was conducted using the Cox proportional hazards model, evaluating the biomarker signature and adjusting for age, Gleason score, baseline PSA, de novo status, disease volume, and ADT intensification. Results: 86 pts were eligible and included. Median age: 65 years (IQR 60-72), median baseline PSA: 29.9 ng/ml (IQR 7.2-23.2) and 64% pts received ADT intensification. 43 pts were categorized as biomarker positive (+) and 43 as biomarker negative (-). Biomarker + pts had a significantly longer median PFS of 67.5 months as compared to 26.9 months in biomarker – pts (HR 0.39, 95% CI HR 0.29 - 0.52, p < 0.001). Biomarker + group was significantly associated with PSA nadir < 0.2 ng/ml (p < 0.001). On multivariate analysis, biomarker + signature was significantly associated with better PFS (Table). Conclusions: CHAI, a novel AI-based digital pathology biomarker is independently associated with PFS in mHSPC setting. After external validation it may serve as a prognostic tool to guide clinical decision-making. Further analysis with a larger sample size will be conducted to evaluate the association with OS. This analysis exemplifies the power of integrating artificial intelligence into medical practice, with a potential to improve outcomes in our patients. Characteristic PFS HR (95% CI) p value Biomarker (+ vs. -) 0.47 (0.24 – 0.91) 0.025 ADT intensification (Yes vs. No) 0.3 (0.16 – 0.7) <0.001 Disease Volume (Low vs. High) 0.37 (0.19 – 0.7) 0.003 Gleason score 1.56 (1.07 – 2.27) 0.021 Age 0.97 (0.93 – 1.00) 0.075 Baseline PSA 1.00 (1.00 – 1.00) 0.061 De novo (Yes vs. No) 1.1 (0.53 – 2.29) 0.793

Association between site of metastases and survival stratification of the IMDC classification in metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology Annalisa Zeppellini, Giorgio Patelli, Martino Pedrani et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.566

566 Background: The IMDC risk model is pivotal for prognostic stratification of mRCC, dividing patients into favorable (FAV), intermediate (INT) and poor-risk (POOR) groups with distinct overall survival (OS) estimates. While valuable for treatment decisions in first line, IMDC does not encompass sites of metastasis, potentially missing a significant prognostic factor. Methods: We retrospectively included mRCC patients receiving first-line therapy at Niguarda Cancer Center, Milan, Italy from 2008 to 2024. The primary aim was to evaluate if specific metastatic sites could redefine IMDC prognostic stratification. OS was analyzed using Kaplan-Meier estimates. Univariate and multivariate Cox regression analyses were performed including variables in the table. Results: 164 patients were eligible for analysis. Bone, liver and nodal metastases were independent negative prognostic factors both in univariate and multivariate analyses (HR 2.83, IC95% 1.78-4.49, p<0.001; HR 1.79, IC95% 1.12-2.85, p=0.014; HR 1.92, IC95% 1.28-2.88, p=0.002, respectively). As expected, FAV IMDC and first-line immunotherapy-based combinations (IO-IO or IO-TKI) were positive prognostic factors (both p<0.001). Having at least one bone and/or liver and/or nodal metastasis (B/L/N) was significantly associated with poorer prognosis and could re-stratify INT IMDC patients into two subpopulations with different OS (HR 1.88, p=0.046): B/L/N-positive INT OS rates were not different from POOR (p=0.193) and B/L/N-negative INT OS rates were comparable to FAV (p=0.193). Conclusions: B/L/N metastases are independent prognostic factors in mRCC, despite being unaddressed by IMDC. Present findings align with prior research supporting the inclusion of metastatic sites in prognostic scores. IMDC classification could be refined with inclusion of metastatic sites to improve prognostic accuracy. Patient characteristics. Age ≥50 147 (90) Sex Male 123 (75) IMDC FAV 42 (26) INT 85 (52) POOR 37 (22) Site of metastasis Bone 40 (24) Liver 31 (19) Nodal 85 (52) Oligometastases (<4) 33 (20) First-line immunotherapy-based combinations 38 (23) Data are shown as number of patients (N) and, within brackets, percentage (%).

Impact of geographic and demographic characteristics on treatment with Lu-PSMA for metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology Abigail Pepin, Abigail Doucette, Samuel U Takvorian et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.153

153 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable and fatal disease. Administration of Lu-PSMA demonstrates improved progression free survival and overall survival in this population (1). Despite this, understanding patient access to and receipt of this therapy is understudied. We aim to characterize the demographics of patients receiving Lu-PSMA at a NCI-designated medical center in Philadelphia, PA after FDA approval. Methods: All patients treated at a single institutional center with Lu-PSMA from April 2023 to October 2024 were included. Demographic characteristics including age at first treatment, race, insurance status, and zip code were extracted from the medical record. Travel distance between a patient’s home and a treatment center was calculated using the Haversine formula as provided by the National Bureau of Economic Research. Median household income was obtained by US Census 2022 American Community Survey. All analyses were performed on Prism (GraphPad, v 10.3.1). Results: A total of 103 patients were included for analysis. The median age at time of first Lu-PSMA treatment was 73 years (range 50-92). 71.8% (n=74) were white and 28.2% were non-white (n=21 Black/African American; n=8 other/multiracial/unknown). All patients were non-Hispanic. All patients were insured (77.7%, n=80, Medicare/Managed Medicare; 3.9%, n=4, Medicaid/managed Medicaid; 18.4%, n=19, private/other insurance). Median distance travelled to a treatment center was 12 miles. About one quarter of patients travelled >25 miles to reach their treatment center (42.7%, n=44, <10 miles; 32.0%, n=33, 10-25 miles; 9.7%, n=10, 25-50 miles; 11.7%, n=12, 50-100 miles; and 3.9%, n=4, >100 miles). Most patients resided in an urban zip code, with a minority (4.9%, n=5) residing in a rural zip code. The median household income by zip code varied from $30,946 to $233,194 (9.7%, n=10, $30-50K; 18.4%, n=19, $50-75K; 20.4%, n=21, $75-100K; 39.8%, n=41, $100-150K; 11.7%, n=12, >150K). The number of Lu-PSMA treatments received was not correlated with distance travelled (F(4,98)=2.4, p=0.05), median household income (F(4,98)=0.5260, p=0.72), or race (p=0.83). There were no differences in travel distance between white and non-white patients (p=0.24). On Kaplan Meier, there were no differences in overall survival in patients that travelled >12 miles for treatment versus those who resided <12 miles from a treatment center (p=0.48). There were no differences in overall survival by race between white with non-white patients (p=0.66). Conclusions: Receipt of Lu-PSMA was not different in populations separated by race, distance to treatment center, or median household income. Increasing travel distance was not associated with receipt of fewer cycles of treatment. Further analysis is needed on whether these factors are associated with referral for and acceptance of Lu-PSMA. 1. Sartor NEJM 2021.

Current impact of ureteral carcinoma amongst racial minorities: Analysis of the National Cancer Database.

Journal of Clinical Oncology Christopher Edwards, Navid Leelani, Katiana Vazquez Rivera et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.675

675 Background: Upper tract cancer is a relatively uncommon type of genitourinary cancer. Lower socioeconomic status and racial disparities have long been associated with worse cancer related outcomes for various types of cancer. Our objective was to determine if racial minorities in the United States were more likely to present with ureteral cancer of stage II or greater. Methods: The National Cancer Database (NCDB) Hospital Comparison Benchmark Reports (HCBR) for ureter cancer from 2013 to 2022 were reviewed. Demographic and clinical data was compared between various races and ethnicities affected to determine any significant differences related to age, stage, insurance status, distance traveled, and education at presentation. Patients were stratified into two groups of patients with stage II or greater and those with less than stage II ureteral cancer. Fischer’s exact test was used to compare the proportion of Caucasian patients with stage II or greater ureteral cancer against patients of other ethnicities. Statistical significance was defined as p<0.05. Results: Within the NCDB HCBR database, there were 26,153 patients with ureter carcinoma spanning 1,238 hospitals, with males comprising 16, 435 (62.8%) and females 9,718 (37.2%). Caucasian patients included most cases at 22,314 (86%), followed by African American patients 1,072 (4.17%), Hispanic patients 1,047 (4.08%), Asian and Pacific Islander patients 871 (3.39%), and Native American patients 73 (0.28%). Overall stage distribution included—0: 9,342 (36.38%); I: 3,711 (14.45%); II: 2,443 (9.51%); III: 2,724 (10.61%); IV: 3,636 (14.16%). A higher proportion of Asian and Pacific Islander patients were more likely to present with Stage II or greater ureteral cancer compared to Caucasian patients (43% vs 33.9%, p<0.001). Furthermore, Asian and Pacific Islander patients were more likely to present with invasive disease (73.6% vs 63.9%, p<0.001). A higher proportion of Asian and Pacific Islander patients were found to be uninsured or have Medicaid, be from a less educated household, and were less likely to travel longer distances for care when compared to Caucasian patients (all p<0.001). Regarding presenting at stage II or greater, there was no significant difference found when comparing Caucasian patients versus African American, Hispanic, or Native American patients. Conclusions: Asian and Pacific Islander patients were more likely to present with stage II or greater ureteral cancer compared to their Caucasian counterparts. Future directions exploring the factors affecting these at-risk groups is vital to properly redirecting resources and improving disparities.

Risk factors of complications after inguinal lymph node dissection in patients with penile cancer.

Journal of Clinical Oncology Yilong Gao, Yanxiang Shao, Xiang Li Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.6

6 Background: Inguinal lymph node dissection (ILND) is a crucial step in the management of patients with penile cancer, particularly for those with lymph node involvement. However, ILND is associated with a significant risk of postoperative complications, which can impact recovery and long-term outcomes. Identifying the risk factors that contribute to these complications may help in improving patients’ quality of life after ILND and perioperative management. Methods: We conducted a retrospective analysis of 192 penile cancer patients who underwent ILND between October 2008 and October 2023 at West China Hospital. 370 surgeries were conducted. Data on patient demographics, tumor characteristics, comorbidities, surgical details, and postoperative outcomes were collected. Complications were classified as minor or major based on the Clavien-Dindo classification. Multivariate logistic regression was performed to identify independent risk factors for each complications. Receiver operating characteristic (ROC) curves were used to analyze the relationship between certain risk factors and postoperative complications and find cut-off points for certain risk factors. Results: The overall complication rate was 87.5%, with most patients experiencing minor complications. Common complications included wound infections (35.4%), lymphatic fistula (50%), lymphocele (42.2%) and lower limb edema (28.6%). Except for the common risk factors, such as surgery type (conventional or minimally invasive, Odds Ratio (OR): 0.157, 95% Confidence Interval (CI): [0.036, 0.692], p =0.014) for wound infection, we additionally found that the shorter retention time of drainage tube (OR: 0.784, 95% CI: [0.724, 0.850], p <0.001) is strongly correlated with subsequent lymphocele, with cut-off points of 6.5 days. And longer retention time of drainage tube (OR: 1.065, 95% CI: [1.031, 1.100], p <0.001) is correlated with wound infection, with cut-off points of 10.5 days. Conclusions: Our study highlights several modifiable and non-modifiable risk factors associated with each complications following ILND in penile cancer patients. Optimizing perioperative care and conducting minimally invasive surgery when possible may reduce postoperative complication rate. And the duration of drainage tube retention is associated with both lymphocele and wound infection. Further prospective studies are warranted to validate these findings.

Evaluating the survival benefits of adjuvant immunotherapy in muscle-invasive urothelial carcinoma: A real-world experience.

Journal of Clinical Oncology Mazyar Zahir, Chirag Doshi, Domenique Escobar et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.750

750 Background: Despite current guidelines recommendations to administer adjuvant nivolumab following radical cystectomy (RC) in patients with adverse pathologies, regardless of prior neoadjuvant chemotherapy (NAC), evidence on the long-term efficacy of ICIs remains sparse. This study aims to evaluate the potential survival benefits of the two most common ICIs, Nivolumab and Pembrolizumab, in patients with muscle-invasive bladder cancer (MIBC) at a single institution. Methods: We queried our IRB-approved, prospectively maintained institutional RC database for all patients who underwent RC from January 2017 (following FDA approval for ICIs in MIBC) to July 2022. Patients with pT3-4a and/or N+ after RC, or ypT2-4a and/or N+ after NAC + RC, were included and categorized into two groups: those who received adjuvant ICI (ICI+) and those who did not (ICI-). Demographic, clinical, and survival data were retrieved from our database. Multivariable Cox regressions were performed to adjust for potential confounding variables. Results: A total of 191 patients were included, with 38 (19.9%) receiving adjuvant ICI (30 Nivolumab and 8 Pembrolizumab). The table outlines the patient characteristics, stratified by adjuvant ICI treatment. With a median follow up of 17.9 months, overall survival (OS) was 97.4% in the ICI+ group and 66.0% in the ICI- group (p = .003). Recurrence-free survival (RFS) was 84.2% and 67.9% in the ICI+ and ICI- groups, respectively (p=.206). in the ICI- group, 10 out of 49 (20.4%) recurrences were local or regional (i.e. urethral or ureteral), while all recurrences (N=6) in the ICI+ group were distant. Multivariable Cox regressions demonstrated that, after adjusting for age and pathological stage, adjuvant ICI was associated with significantly improved OS (HR = 0.08 [95%CI: 0.01, 0.59], p = .013), but not RFS (HR = 0.43 [95%CI: 0.18, 1.04], p = .062). Conclusions: Our results corroborated the beneficial effect of ICIs on OS. Although the improvement in RFS did not reach statistical significance, ICIs showed a trend toward positive clinical impact. A notable finding was the potential for ICIs to alter the recurrence pattern in MIBC. Although limited by a small sample size, this study represents one of the first real-world evaluations of adjuvant ICI efficacy in a single-institution cohort. Demographics and baseline clinical characteristics. ICI+ (N=38) ICI- (N=153) p Age (years) 68.7 ± 8.6 71.6 ± 10.4 .060 Sex (Male) 27 (71.1%) 118 (77.1%) .433 Charleson Comorbidity Index 0 9 (23.7%) 31 (20.3%) .886 1 6 (15.8%) 27 (17.6%) ≥ 2 23 (60.5%) 95 (62.1%) Pathological staging OC (< (y)pT2; pN0) 3 (7.9%) 29 (19.0%) .013 EV (> (y)pT2; pN0) 11 (28.9%) 67 (43.8%) LN+ (pN+) 24 (63.2%) 57 (37.2%) Neoadjuvant Chemotherapy (yes) 30 (79.0%) 85 (55.6%) .008

Real-world safety of first-line (1L) therapies for locally advanced or metastatic urothelial cancer (la/mUC) in the US.

Journal of Clinical Oncology Amanda Nizam, Mairead Kearney, Valerie A. Morris et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.759

759 Background: The 1L treatment landscape in la/mUC has evolved rapidly, encompassing platinum-based chemotherapy, immune checkpoint inhibitors (ICIs), and antibody-drug conjugates, and including monotherapy and combination regimens. Real-world data on adverse events (AEs) with novel 1L therapies are limited. This study aims to fill this evidence gap by comprehensively characterizing the incidence of real-world treatment-emergent AEs (rwTEAEs) with 1L regimens for la/mUC. Methods: This is a retrospective observational cohort study of patients (pts) in the nationwide Flatiron Health electronic health record–derived deidentified database. The study population included adults diagnosed with la/mUC who initiated 1L treatment with a regimen of interest (Table) since January 1, 2016. Machine learning was used to extract clinician documentation of a prespecified list of 30 rwTEAEs from 1L treatment initiation to the earliest of 90 days after last 1L dose, start of subsequent treatment, or death. Occurrence of rwTEAEs (overall incidence and exposure-adjusted rate based on treatment-months) was described across groups. Results: Of 5,235 pts who met study criteria, 73% were male, median age was 74 years (IQR, 66-80), 70% were White, 66% had ECOG PS of 0-1, and practice setting was community/academic/both in 79%/14%/7%. The most common rwTEAEs in the overall cohort were fatigue (71%), anemia (48%), nausea (48%), and loss of appetite (47%). When adjusted for time on treatment, relative rates of some rwTEAEs differed greatly from incidences (Table). Conclusions: These data aid in understanding the real-world safety of 1L treatment options for la/mUC and help inform the development of patient supportive care plans by population-based healthcare decision-makers. Time on treatment should be considered when interpreting the incidence of safety events. Incidence of rwTEAEs, % (rate per 1,000 person-months on treatment) Overall N=5,235 Enfortumab vedotin + pembrolizumabn=198 ICI monotherapy n=2,146 Cisplatin-based chemo without avelumab 1LMn=1,372 Carboplatin-based chemo without avelumab 1LMn=1,140 Cisplatin-based chemo with avelumab 1LMn=197 Carboplatin-based chemo with avelumab 1LMn=182 Fatigue 70.7 (266.6) 68.7 (234.3) 62.2 (172.0) 75.7 (406.9) 72.5 (380.4) 95.4 (371.3) 96.7 (375.5) Weight loss 34.6 (66.6) 47.0 (102.2) 32.9 (53.2) 33.0 (84.1) 32.5 (84.9) 51.8 (35.1) 48.4 (34.6) Diarrhea 30.7 (58.2) 45.0 (98.4) 30.2 (49.5) 27.8 (66.9) 29.5 (74.9) 40.6 (24.9) 40.7 (29.1) Rash 20.3 (35.6) 47.0 (108.7) 21.9 (33.5) 14.7 (32.5) 15.3 (34.4) 34.0 (20.1) 31.9 (20.8) Pruritus 14.5 (24.3) 36.9 (72.5) 19.9 (30.7) 6.1 (12.4) 7.8 (16.4) 23.4 (13.0) 21.4 (13.4) Peripheral neuropathy 5.2 (7.6) 17.7 (29.0) 3.6 (4.4) 5.3 (10.9) 3.8 (7.6) 16.8 (8.4) 6.6 (2.8) Hyperglycemia 3.9 (5.6) 8.6 (12.7) 3.4 (4.1) 3.9 (7.9) 2.7 (5.4) 9.1 (4.0) 5.5 (2.6) 1LM, 1L maintenance; chemo, chemotherapy.

Plasma proteome-based integrative prognostic nomogram in metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology Manish Kohli, Joseph Finklestein, Xingyue Huo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.225

225 Background: Currently non-specific clinical factors including non-tumor biology proteins (Alkaline Phosphatase-ALK, LDH, albumin) are used for identifying high, intermediate or low prognostic survival risk in mCRPC. We integrated these biomarkers with plasma proteins overexpressed exclusively in mCRPC to develop patient-centric nomograms for estimating 1,2 and 3-year (yr) overall survival (OS) probabilities. Methods: Proteomic profiling of plasma for 3072 proteins using Olink Explore NGS platform was performed in 32 local stage prostate cancer, 123 metastatic hormone-sensitive (mHSPC) and 157 mCRPC state samples (Total N=312) in a clinically annotated real-world cohort study that enrolled patients (pts) between 2020 and 2024. Protein assays were measured in normalized protein expression (NPX) units through a normalization process. We compared NPX values of all protein assays across all three cancer states to identify Differentially Expressed Proteins (DEPs) exclusively overexpressed in mCRPC using t-test with multiple corrections. Clinical outcome in the mCRPC was OS. A composite score was generated aggregating DEPs overexpressed in mCRPC with OS, by multiplying each individual DEP’s univariate-level survival Hazard Ratio (HR) coefficient with their corresponding NPX value. The composite score range for the mCRPC cohort (N=121 pts) was dichotomized above and below the cohort median as “High” and “Low” and evaluated for survival using Cox Proportional Hazard Regression along with current prognostic protein biomarkers (ALK, LDH, albumin) at the univariate followed by multi-variable analysis (MVA) for variables observed with univariate significance (P<0.05). Prognostic nomograms integrating MVA significant clinical factors with the DEP composite score was developed and performance of the nomogram with and without the composite score for estimating 1,2 and 3-years survival probabilities was determined using ROC curves and Area Under Curve (AUC). All analyses were conducted in RStudio. Results: Median OS of the mCRPC cohort (N=121) was 28 months (range: 0.3-45). There were 353/3072 DEPs exclusive to mCRPC and 19/353 DEPs were associated with OS (univariate P<0.05) (SCRN1, GP2, NFU1, DPY30, SNRPB2, KRT19, FKBP5, PGD, IL6, L3HYPDH, MYDGF, DH1, IQGAP2, TOMM20, YAP1, CLGN, IMMT, PKD2, PALM2). MVA Hazard Ratios (HR) with 95% CIs for nomogram input included: DEP score HR-3.48 (1.77-6.83; P<0.0003); LDH: HR-1.01 (1-1; P=0.13); ALK: HR-1 (1-1; P=0.000035); Albumin: HR-0.61 (0.24-1.51; P=0.28). AUCs for estimating mCRPC OS probabilities integrating the DEP score with current factors versus clinical factors alone increased to 0.87 from 0.85 (1-yr); to 0.78 from 0.73(2-yr) and to 0.79 from 0.70 (3-yr). Conclusions: A patient-centric approach using nomograms to estimate survival in mCRPC which includes novel protein classifiers can enhance current prognostication models.

Correlates of immunotherapy response in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes.

Journal of Clinical Oncology Razane El Hajj Chehade, Karl Semaan, Ze Zhang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.593

593 Background: Immune checkpoint inhibitors (ICIs) are a mainstay of treatment for metastatic clear cell renal cell carcinoma (mccRCC). With a growing number of treatment options for mccRCC, biomarkers are needed to guide treatment selection by predicting benefit from ICIs. Cell-free DNA (cfDNA)-based assays that measure tumor DNA in plasma are promising biomarkers for treatment response in several cancers, but their role in RCC remains unclear. Here, we tested whether epigenomic profiling of cell-free DNA can identify or predict radiographic responses to immunotherapy in mccRCC. Methods: Plasma samples were obtained from 180 patients (400 total samples collected, up to 4 samples per patient) with mccRCC enrolled in the DOD-funded Kidney Cancer Research Consortium ctDNA study (NCT04883827). Patients received an immune checkpoint inhibitor and were categorized as non-responders or responders based on CT scan results obtained at 3- or 6-months following treatment initiation. Cell-free chromatin immunoprecipitation sequencing (cfChIP-seq) was performed on patient plasma to profile H3K4me3, a histone modification associated with active gene promoters. DNA methylation was profiled with cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq). H3K4me3 signal at the promoters of ccRCC-associated genes variation between pre-treatment and on-treatment timepoints was assessed for non-responders and responders. We calculated changes in H3K4me3 signal for on- and pre-treatment plasma draws. We then compared these changes between non-responders and responders using the Wilcoxon sum-rank test. The immune cell types contributing to cfDNA were inferred from cfMeDIP-seq data. Results: Comparing pre- and on-treatment timepoints drawn between 1-5 months after starting therapy, cfDNA promoter H3K4me3 at RCC-associated genes was concordant with radiographic response in 10 of 11 patients (91%), with signal increasing from pre- to on-treatment samples in 6 of 7 non-responders (86%) and decreasing in 4 of 4 responders (100%). The median change in H3K4me3 differed significantly for non-responders and responders (p = 0.02). Analysis of cfDNA methylation profiles identified a higher proportion of memory CD8 T cell-derived cfDNA in non-responders compared to responders in pre-treatment samples (p = 0.003) Conclusions: This pilot study suggests that epigenomic profiling of cfDNA may identify pre-treatment and on-treatment biomarkers of ICI response. Profiling of larger cohorts is underway to test the generalizability of these findings.

Circulating tumor DNA levels and related kinetics as prognostic biomarkers for clinical outcomes in mCRPC: A post hoc analysis of CM 7DX.

Journal of Clinical Oncology Karim Fizazi, Fred Saad, Teresa Alonso Gordoa et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.252

252 Background: Liquid biopsy assays in mCRPC are utilized for treatment eligibility of PARP inhibitors (HRR) and Pembrolizumab (MSI High). These ctDNA targeted gene panels provide translational data beyond gene mutations. Tumor Fraction (TF), the percentage of cfDNA from tumor, is a promising prognostic efficacy biomarker in pre-chemo mCRPC, and a potential predictive biomarker to post-chemo PSMA radioligand therapy. Methods: We analyzed ctDNA run with Illumina-TSO500 from the CA209-7DX Ph3 mCRPC trial (Nivo+chemo vs. Chemo in chemo-naïve mCRPC) to determine: TF at baseline or changes at Cycle6 Day1 (C6D1). TF at each timepoint was determined through the maximum somatic allelic frequency. Results: We present a combined analysis of treatment arms as both showed similar association between clinical outcomes and TF levels as well as clearance. Out of 1030 ITT patients TF data was available for 527 (51%) patients. Patients in the highest TF tertile had TF of ≥4.6% and TF<0.3% for the lowest tertile. Patients in the lowest TF tertile had 10 months longer overall survival (OS) to the highest TF tertile (p<0.001). Patients in the highest TF tertile demonstrated higher hazard ratio for OS (HR 3.42,[2.34-4.98] p<0.001) and rPFS (HR 1.95 [1.47-2.59], p<0001) over lowest tertile. This differential was maintained across arms and indicates that TF is a strong prognostic biomarker. High TF outperformed common stratification factors (prior exposure to chemo in CSPC or novel ARPIs) for poor prognostication in a multivariate analysis. TF high patients have higher rates of AR-Amp/AR-LBD mutations (72.6%) than TF low (28.8%). Patients with TF clearance, defined as TF < 1% at C6D1 had 8 months mOS advantage over patients with a TF >1% at baseline and on-treatment. TF clearance strongly correlated with OS (HR=0.42 [0.28-0.62], p<0.001), rPFS benefit (HR=0.24 [0.17-0.34], p<0.001) and PSA response (28% vs. 62%) regardless of treatment arm. Conclusions: This data advocates for plasma TF as a robust prognostic biomarker and as a potential stratification opportunity in mCRPC clinical trials. TF clearance may act as an early indicator of treatment response and hence can be an important monitoring tool for mCRPC patient management. Clinical trial information: NCT04100018 .

Unraveling the dietary impact: Associations between ultra-processed foods and prostate cancer in a two-decade study.

Journal of Clinical Oncology Elise Katsnelson, Derek Isrow, Crystal Taswell et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.135

135 Background: Prostate cancer is a leading cause of cancer-related morbidity in men, and emerging research suggests that dietary patterns, particularly involving processed foods, may play a role in its development. This study aims to explore the association between NOVA-classified food consumption and prostate cancer. Methods: Data from the National Health and Nutrition Examination Survey (NHANES 1999-2018) was analyzed. A sensitivity analysis was performed. Men aged 20 and older with a diagnosis of prostate cancer (n=731) and without any cancer (n=20,972) were contrasted. The mean daily caloric intake from various NOVA food categories was analyzed using independent t-tests, then corrected using Benjamini-Hochberg (p<0.05). Subgroup analyses were conducted via Welch two-sample t-tests for age and BMI, while Chi-Square tests were used for race, education level, birth country, and military status. Results: Men with prostate cancer had a higher intake of the following NOVA group 4 ultra-processed foods: “cakes, cookies pies, pancakes” (p=0.031), “ice cream, ice pops, and frozen yogurts” (p<0.001), “sugared breakfast cereals” (p<0.001). They also had a higher intake of certain group 1 unprocessed or minimally processed foods: “roots and tubers” (p=0.019) and “fruits including juices” (p<0.001). Men without cancer had a higher intake of certain NOVA 1 unprocessed or minimally processed foods: meat/poultry (p<0.001), grains (p=0.002), pasta (p=0.025). They also ate more oils (NOVA 2 processed culinary ingredients, p=0.003), NOVA 3 processed foods like cheese (p<0.001), and many NOVA 4 foods like salty snacks (p=0.002), pizza (p<0.001), sandwiches/hamburgers (p=0.030), potato products (p<0.001), sauces/dressing/gravies (p=0.001), soft drinks (p<0.001), and sweetened beverages (p<0.001). Subgroups analyses revealed a greater association with prostate cancer for people with older age, Non-Hispanic Black and Non-Hispanic White races, being US-born, having a higher education, and serving in the military. Conclusions: To our knowledge, this is the largest study evaluating dietary behavior in the context of food processing and prostate cancer prevalence. We identified a high risk dietary pattern associated with industrially processed, calorically dense, and high glycemic index foods; conversely, a low risk dietary pattern was associated with minimally processed Mediterranean diets and, interestingly, highly processed Western diets.

A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).

Journal of Clinical Oncology Yohann Loriot, Arlene O. Siefker-Radtke, Terence W. Friedlander et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps898

TPS898 Background: Zelenectide pevedotin (zele; BT8009) is a Bicycle Toxin Conjugate (BTC), comprising a highly selective bicyclic peptide targeting Nectin-4 linked to the cytotoxin monomethyl auristatin E (MMAE) via a cleavable linker. Nectin-4 is an adhesion molecule commonly expressed in many tumor types, including la/mUC, and is a validated therapeutic target (Hoffman-Censits 2021). Zele has a low molecular weight and short plasma half-life, with potential to rapidly penetrate solid tumors and reduce toxicity by minimizing exposure to normal tissue (Rigby 2022). Results from the ongoing Phase 1/2 clinical trial of zele (NCT04561362) indicate preliminary antitumor activity and a tolerable safety profile in patients (pts) with advanced malignancies including UC (Baldini 2023). This global, open label, Phase 2/3 multicenter adaptive study aims to evaluate the safety and efficacy of zele as monotherapy, or combined with pembrolizumab (pembro), vs chemotherapy in pts with la/mUC (NCT06225596/BT8009-230; Duravelo-2). Methods: The trial will enroll n≤956 adult pts in 2 cohorts. Cohort 1 will include n≤641 previously untreated pts eligible for platinum-based chemotherapy. Cohort 2 will include n≤315 pts with ≥1 prior systemic therapy, excluding enfortumab vedotin or other MMAE-based therapy. Pts must have la/mUC of the renal pelvis, ureter, bladder, or urethra, ECOG performance status ≤2 (Cohort 1) or ≤1 (Cohort 2), and adequate organ function. Cohort 1 will be randomized 1:1:1 to receive: 1) zele 5 mg/m 2 on days [D]1, 8, and 15 + pembro 200 mg on D1; 2) zele 6 mg/m 2 on D1 and 8 + pembro 200 mg on D1; or 3) chemotherapy (gemcitabine + cisplatin / carboplatin, followed by avelumab maintenance in appropriate patients). Cohort 2 will be randomized 1:1 to receive: 1) zele 5 mg/m 2 on D1, 8, and 15 or 2) zele 6 mg/m 2 on D1 and 8. Cycle lengths will be 21D (28D for avelumab). After 30 pts in each dose arm have 9 weeks follow up, an interim analysis will determine the optimal dose of zele + pembro (Cohort 1) or zele monotherapy (Cohort 2) to be used for the rest of the study. An additional Cohort 2 arm, optimal dose of zele + pembro, will open after completion of the interim analysis. Discontinuation criteria include planned completion of therapy, progressive disease, and intolerable toxicity. Primary endpoints are progression-free survival (PFS; Cohort 1) and objective response rate (ORR; Cohort 2) assessed by blinded independent central review. Secondary endpoints are ORR (Cohort 1), PFS (Cohort 2), and overall survival, duration of response, disease control rate, safety/tolerability, and health-related quality of life (Cohorts 1 and 2). Pharmacokinetics, incidence/titers of antidrug antibodies, and tumor/peripheral biomarkers are exploratory endpoints. Efficacy endpoints will be assessed per RECIST v1.1. This study is actively recruiting. Clinical trial information: NCT06225596 .